Regulatory applications submitted to FDA and EMA for Skyrizi in Ulcerative Colitis.- AbbVie.

"While there has been advancement in therapies to treat ulcerative colitis, there is still an ongoing need for additional treatments to help those seeking relief from its disruptive effects," said Roopal Thakkar, M.D., senior vice president, development, regulatory affairs and chief medical officer, AbbVie. "These submissions demonstrate our continued commitment to helping people living with IBD, and we look forward to providing a potential new treatment option for the management of ulcerative colitis."

Applications to the FDA and EMA are supported by data from two Phase III clinical trials: an induction study, INSPIRE, and a maintenance study, COMMAND. Significantly more patients treated with risankizumab 1200 mg IV at week 12 in the induction study and 180 mg or 360 mg SC at week 52 in the maintenance study achieved the primary endpoint of clinical remission (per Adapted Mayo Score), compared to patients receiving placebo. Additionally, more risankizumab-treated patients in both the induction and maintenance studies achieved the key secondary endpoints of endoscopic improvement (endoscopic subscore ?1 without evidence of friability) and histologic endoscopic mucosal improvement (HEMI, defined as endoscopic subscore less than 1 without evidence of friability and Geboes score less than 3.1) compared to placebo.

The safety results in INSPIRE and COMMAND were generally consistent with the safety profile of risankizumab observed in previous studies across other indications, with no new safety risks observed. Risankizumab (Skyrizi) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.